A Phase II Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma
The purposes of this study are:
- To estimate the objective response rate (CR, CRu, PR) to six cycles of concurrent
fludarabine and rituximab in patients with disseminated or recurrent CD5-, CD10-, CD20+
low-grade B cell lymphomas.
- To assess the safety of fludarabine and rituximab in this patient population.
- To describe the progression-free survival at one year.
- To examine the association between clonal cytogenetic abnormalities identified by FISH,
and the objective response rate as well as the progression-free survival at one year.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Determine the objective response rate following six cycles of fludarabine and rituximab in this population
Jennifer R. Brown, MD, PhD
Dana-Farber Cancer Institute
United States: Institutional Review Board
|University of Rochester Cancer Center||Rochester, New York 14642|
|Beth Israel Deaconess Medical Center||Boston, Massachusetts 02215|
|Dana-Farber Cancer Institute||Boston, Massachusetts 02115|
|Massachusetts General Hospital||Boston, Massachusetts 02114-2617|